Esteban Santos - Amgen Executive Vice President Operations
| AMGN Stock | USD 279.85 0.16 0.06% |
President
Mr. Esteban Santos is the Executive Vice President, Operations of the Company. Mr. Santos became Executive Vice President, Operations in July 2016. Mr. Santos joined the Company in 2007 as Executive Director, Manufacturing Technologies. From October 2008 to May 2013, Mr. Santos held a number of Vice President roles at the Company in engineering, manufacturing, site operations and drug product. From May 2013 to July 2016, Mr. Santos was Senior Vice President, Manufacturing. Prior to joining the Company, Mr. Santos served as Site General Manager for JJs Cordis operation in Puerto Rico. Prior to JJ, Mr. Santos held several management positions in GEs industrial and transportation businesses. since 2016.
| Age | 56 |
| Tenure | 8 years |
| Address | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.046 % which means that it generated a profit of $0.046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5572 %, meaning that it created $0.5572 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 27th of November 2024, Return On Equity is likely to grow to 1.13, while Return On Tangible Assets are likely to drop 0.12. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 27th of November 2024, Asset Turnover is likely to grow to 0.51, while Total Current Assets are likely to drop about 15.2 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jeffrey Heeter | Alcoa Corp | 58 | |
| Wade Allen | Brinker International | 43 | |
| Joseph Taylor | Brinker International | 65 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Aaron White | Brinker International | 47 | |
| Steve Provost | Brinker International | 59 | |
| Roy Harvey | Alcoa Corp | 49 | |
| Marc Zahr | Blue Owl Capital | 44 | |
| Douglas Comings | Brinker International | 50 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Charles Lousignont | Brinker International | 65 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| John Slaven | Alcoa Corp | 62 | |
| Pankaj Patra | Brinker International | 47 | |
| Richard Badgley | Brinker International | 52 | |
Management Performance
| Return On Equity | 0.56 | ||||
| Return On Asset | 0.046 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, VP Officer | ||
| Jonathan JD, General VP | ||
| Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | ||
| Murdo Gordon, Executive Vice President of Global Commercial Operations | ||
| Peter Griffith, Executive CFO | ||
| James MD, Executive Officer | ||
| Nancy Grygiel, Senior Officer | ||
| Ian Thompson, Senior Operations | ||
| Scott Skellenger, Senior Officer | ||
| Darryl MD, Senior Medical | ||
| Derek Miller, Senior Resources | ||
| Justin Claeys, Vice Relations | ||
| Esteban Santos, Executive Vice President Operations | ||
| Matthew Busch, Chief Finance | ||
| Jonathan Graham, Senior Vice President General Counsel, Secretary | ||
| Kave Niksefat, Senior Access | ||
| Jerry Murry, Senior Development | ||
| Mike Zahigian, Senior Officer | ||
| Alan Russell, Vice Biologics | ||
| David MD, Executive Officer | ||
| Arvind Sood, IR Contact Officer |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.56 | ||||
| Return On Asset | 0.046 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 201.9 B | ||||
| Shares Outstanding | 537.53 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 81.03 % | ||||
| Number Of Shares Shorted | 8.82 M | ||||
| Price To Earning | 22.74 X |
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
| 0.61 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.81 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Amgen Stock
| 0.79 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.72 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.38 | MNOV | MediciNova | PairCorr |
| 0.35 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.32 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.621 | Dividend Share 8.88 | Earnings Share 7.84 | Revenue Per Share 60.641 | Quarterly Revenue Growth 0.232 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.